[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN115843296A - Cdk9抑制剂及其用途 - Google Patents

Cdk9抑制剂及其用途 Download PDF

Info

Publication number
CN115843296A
CN115843296A CN202180049342.0A CN202180049342A CN115843296A CN 115843296 A CN115843296 A CN 115843296A CN 202180049342 A CN202180049342 A CN 202180049342A CN 115843296 A CN115843296 A CN 115843296A
Authority
CN
China
Prior art keywords
methyl
alkyl
halo
compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180049342.0A
Other languages
English (en)
Other versions
CN115843296B (zh
Inventor
彭作中
贾继林
胡佳琪
崔茜
武怡舟
易云菲
陈秋红
王婕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Maisheng Technology Co ltd
Original Assignee
Pharmablock Sciences Nanjing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmablock Sciences Nanjing Inc filed Critical Pharmablock Sciences Nanjing Inc
Publication of CN115843296A publication Critical patent/CN115843296A/zh
Application granted granted Critical
Publication of CN115843296B publication Critical patent/CN115843296B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

本申请提供一种式(I)化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其可药用的盐，以及其用于制备由CDK9介导的疾病药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202180049342.0A 2020-08-07 2021-08-06 Cdk9抑制剂及其用途 Active CN115843296B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010789162 2020-08-07
CN2020107891623 2020-08-07
PCT/CN2021/111073 WO2022028556A1 (zh) 2020-08-07 2021-08-06 Cdk9抑制剂及其用途

Publications (2)

Publication Number Publication Date
CN115843296A true CN115843296A (zh) 2023-03-24
CN115843296B CN115843296B (zh) 2024-03-08

Family

ID=80117061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049342.0A Active CN115843296B (zh) 2020-08-07 2021-08-06 Cdk9抑制剂及其用途

Country Status (8)

Country Link
US (1) US20230271942A1 (zh)
EP (1) EP4194450A4 (zh)
JP (1) JP7537002B2 (zh)
KR (1) KR20230038740A (zh)
CN (1) CN115843296B (zh)
AU (1) AU2021323245B2 (zh)
CA (1) CA3188521A1 (zh)
WO (1) WO2022028556A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568529A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
CN102143953A (zh) * 2008-03-26 2011-08-03 诺丁汉大学 嘧啶、三嗪类化合物以及它们作为药剂的用途
CN103562184A (zh) * 2011-03-02 2014-02-05 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
CN104822380A (zh) * 2012-08-23 2015-08-05 维罗斯塔蒂克斯公司 新颖的4,6-二取代的氨基嘧啶衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1901747A2 (en) 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
EP2069333A1 (en) * 2006-09-21 2009-06-17 Novartis Ag Pyrrole derivatives useful for the treatment of cytokine-mediated diseases
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2361902A4 (en) * 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
EP3176154B1 (en) * 2010-11-01 2019-02-20 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
US20140303163A1 (en) 2011-03-24 2014-10-09 Ying Luo Use of kinase inhibitors in preventing and treating inflammatory disorder
JP6259463B2 (ja) 2012-11-08 2018-01-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物
ES2792979T3 (es) * 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
CR20210297A (es) 2015-06-29 2021-09-29 Astrazeneca Ab Derivados de amidas policiclicas como inhibidores de cdk9 (divisional exp. 2017-596)
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568529A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
CN102143953A (zh) * 2008-03-26 2011-08-03 诺丁汉大学 嘧啶、三嗪类化合物以及它们作为药剂的用途
CN103562184A (zh) * 2011-03-02 2014-02-05 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
CN104822380A (zh) * 2012-08-23 2015-08-05 维罗斯塔蒂克斯公司 新颖的4,6-二取代的氨基嘧啶衍生物

Also Published As

Publication number Publication date
AU2021323245A1 (en) 2023-03-02
CN115843296B (zh) 2024-03-08
JP2023537586A (ja) 2023-09-04
EP4194450A4 (en) 2024-10-30
AU2021323245B2 (en) 2024-02-15
EP4194450A1 (en) 2023-06-14
WO2022028556A1 (zh) 2022-02-10
CA3188521A1 (en) 2022-02-10
KR20230038740A (ko) 2023-03-21
JP7537002B2 (ja) 2024-08-20
US20230271942A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CN109952303B (zh) Tyk2抑制剂及其用途
CN113004278B (zh) 作为fgfr抑制剂的双环杂环
EP2124951B1 (en) 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
AU2018237123B2 (en) Bruton's tyrosine kinase inhibitors
JP2016518316A (ja) Ｍｋ２阻害剤およびそれらの使用
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
JP7261752B2 (ja) 新規キノリノン化合物
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
KR20210105375A (ko) Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도
CN116635371A (zh) 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
CN111655690A (zh) 吡唑并吡啶酮化合物
CN111655689A (zh) 吡唑并吡啶酮化合物
CN115843296B (zh) Cdk9抑制剂及其用途
CN113227100B (zh) 噻吩并吡啶酮化合物
RU2827549C2 (ru) Соединения тиенопиридинона
CN117730080A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231124

Address after: Room 398, Building A, Phase I, Zhongdan Ecological Life Science Industrial Park, No. 3-1 Xinjinhu Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210032

Applicant after: Nanjing Maisheng Technology Co.,Ltd.

Address before: No.10 Xuefu Road, Jiangbei new district, Nanjing, Jiangsu 210032

Applicant before: PHARMABLOCK SCIENCES (NANJING) , Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant